CIK 0001806310
- Non-accelerated filer
- Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 843199512
- Phone
- +1 214-612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Financial Officer sold 33,000 shares at $2.33 ($76,890)
- 4 Open-market buy 10% owner bought 16,466,667 shares at $0.90 ($14,820,000)
- 4 Open-market buy Director bought 777,778 shares at $0.90 ($700,000)
- 4 Open-market buy Chief Executive Officer bought 444,444 shares at $0.90 ($400,000)
- 4 Open-market buy Director bought 111,111 shares at $0.90 ($100,000)
- 4 Open-market sale 10% owner sold 85,872 shares at an average $0.71 ($60,771)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale 10% owner sold 28,608 shares at an average $0.70 ($20,119)
- 4 Open-market sale 10% owner sold 434,615 shares at an average $0.71 ($307,844)
- 4 Grant or award Chief Financial Officer acquired 6,230 shares (grant or award)
- 4 Open-market buy President and Head of R&D bought 5,000 shares at $0.68 ($3,400)
- 4 Other acquisition 10% owner acquired 251,296 shares (other)
- 4 Grant or award Chief Financial Officer acquired 18,691 shares (grant or award)
- 4 Derivatives Options or other derivatives
Page 3 of 6 · 120 filings